The U.S. Court of Appeals for the Federal Circuit (CAFC) on Thursday upheld the District of Delaware’s grant of judgment as a matter of law (JMOL) that Amgen’s patent claims covering its Repatha cholesterol treatment were invalid for lack of enablement. The court found that Amgen’s composition claims were defined by meeting functional limitations, rather than by structure, and that the patent specifications didn’t enable the preparation of the full scope of the claims without undue experimentation. Judge Lourie authored the opinion. Amgen v. Sanofi (CAFC, Feb. 11, 2020)
Recent Posts
- Massive Replication of Comments Submitted to NIST March-In Rights RFI Should Cause Concern
- Lourie Dissents from CAFC View that Heart Valve Transport was Not Infringing
- Rader’s Ruminations – Patent Eligibility II: How the Supreme Court Ignored Statute and Revived Its Innovation-Killing Two-Step
- Other Barks and Bites for Friday, March 22: French Watchdog Hits Google with €250 Million for IP Breaches; C4IP Releases First Congressional Innovation Scorecard; EPO Sees Record Number of Patent Applications
- ‘Tic Tac Fruit’ Gaming System Claims Fail CAFC’s Eligibility Analysis